Institutional profile: the national Swedish academic drug discovery & development platform at SciLifeLab.

Per I Arvidsson, Kristian Sandberg, Kjell S Sakariassen
Author Information
  1. Per I Arvidsson: Science for Life Laboratory, Drug Discovery & Development Platform & Division of Translational Medicine & Chemical Biology, Department of Medical Biochemistry & Biophysics, Karolinska Institutet, Stockholm, Sweden.
  2. Kristian Sandberg: Science for Life Laboratory, Drug Discovery & Development Platform & Organic Pharmaceutical Chemistry, Department of Medicinal Chemistry, Uppsala Biomedical Center, Uppsala University, Sweden.
  3. Kjell S Sakariassen: KellSa s.a.s., Str. Campo e Zampe 12, I-13900 Biella, BI, Italy.

Abstract

The Science for Life Laboratory Drug Discovery and Development Platform (SciLifeLab DDD) was established in Stockholm and Uppsala, Sweden, in 2014. It is one of ten platforms of the Swedish national SciLifeLab which support projects run by Swedish academic researchers with large-scale technologies for molecular biosciences with a focus on health and environment. SciLifeLab was created by the coordinated effort of four universities in Stockholm and Uppsala: Stockholm University, Karolinska Institutet, KTH Royal Institute of Technology and Uppsala University, and has recently expanded to other Swedish university locations. The primary goal of the SciLifeLab DDD is to support selected academic discovery and development research projects with tools and resources to discover novel lead therapeutics, either molecules or human antibodies. Intellectual property developed with the help of SciLifeLab DDD is wholly owned by the academic research group. The bulk of SciLifeLab DDD's research and service activities are funded from the Swedish state, with only consumables paid by the academic research group through individual grants.

Keywords

References

  1. Sci Rep. 2015 Sep 22;5:14118 [PMID: 26392291]
  2. Cell Chem Biol. 2016 Nov 17;23 (11):1428-1438 [PMID: 27984028]
  3. Nat Commun. 2016 Mar 24;7:11040 [PMID: 27010513]
  4. Science. 2015 Jan 23;347(6220):1260419 [PMID: 25613900]
  5. Methods Mol Biol. 2017;1575:175-187 [PMID: 28255880]
  6. J Med Chem. 2016 Sep 22;59(18):8577-92 [PMID: 27607569]
  7. Autophagy. 2014 Jan;10(1):57-69 [PMID: 24169509]
  8. ACS Chem Biol. 2013 Dec 20;8(12):2605-6 [PMID: 24354290]
  9. Nature. 2013 Oct 31;502(7473):711-2 [PMID: 24180008]
  10. Oncotarget. 2016 Nov 8;7(45):73200-73215 [PMID: 27689322]
  11. Nat Rev Drug Discov. 2016 Oct;15(10 ):679-98 [PMID: 27516170]
  12. Nature. 2014 Apr 10;508(7495):215-21 [PMID: 24695224]
  13. J Pharm Sci. 2016 Feb;105(2):1017-21 [PMID: 26869442]
  14. J Biomol Screen. 2015 Mar;20(3):372-81 [PMID: 25520371]
  15. Mol Cancer Ther. 2014 Jul;13(7):1964-76 [PMID: 24755197]
  16. Cancer Res. 2017 Feb 15;77(4):937-948 [PMID: 27899380]
  17. Protein Eng Des Sel. 2016 Oct;29(10 ):427-437 [PMID: 27590051]
  18. Drug Discov Today. 2016 Oct;21(10 ):1690-1698 [PMID: 27373760]
  19. ChemistryOpen. 2015 Jun;4(3):342-62 [PMID: 26246997]
  20. J Lab Autom. 2016 Feb;21(1):178-87 [PMID: 26246423]
  21. Nat Rev Drug Discov. 2014 Jan;13(1):15-6 [PMID: 24378794]
  22. Nat Rev Drug Discov. 2013 Nov;12(11):811-2 [PMID: 24172316]
  23. Angew Chem Int Ed Engl. 2017 Apr 3;56(15):4100-4109 [PMID: 27958674]
  24. Assay Drug Dev Technol. 2016 Apr;14 (3):180-93 [PMID: 27078680]
  25. Apoptosis. 2014 Sep;19(9):1411-8 [PMID: 24923770]
  26. ChemMedChem. 2015 Mar;10(3):455-60 [PMID: 25630705]
  27. PLoS One. 2016 Feb 24;11(2):e0148762 [PMID: 26910052]
  28. Ann Oncol. 2016 Dec;27(12 ):2275-2283 [PMID: 27827301]
  29. Science. 2010 May 14;328(5980):805 [PMID: 20466895]
  30. Nat Rev Drug Discov. 2011 Jun;10(6):409-10 [PMID: 21629285]
  31. J Med Chem. 2016 Mar 10;59(5):2083-93 [PMID: 26805033]

Word Cloud

Created with Highcharts 10.0.0SciLifeLabacademicresearchSwedishdiscoverydrugDDDStockholmdevelopmentUppsalanationalsupportprojectsUniversitytherapeuticsmoleculesgroupScienceLifeLaboratoryDrugDiscoveryDevelopmentPlatformestablishedSweden2014onetenplatformsrunresearcherslarge-scaletechnologiesmolecularbiosciencesfocushealthenvironmentcreatedcoordinatedeffortfouruniversitiesUppsala:KarolinskaInstitutetKTHRoyalInstituteTechnologyrecentlyexpandeduniversitylocationsprimarygoalselectedtoolsresourcesdiscovernovelleadeitherhumanantibodiesIntellectualpropertydevelopedhelpwhollyownedbulkDDD'sserviceactivitiesfundedstateconsumablespaidindividualgrantsInstitutionalprofile:&platformmedicalantibodybiopharmapharmasmall

Similar Articles

Cited By